Effect of stereochemistry on ester hydrolysis by cholinesterases: Implications for radiotracer design by Snyder, Scott E. et al.
SIIO Symposium Abstracfs 
EFFECT OF STEREOCHEMISTRY ON ESTER HYDROLYSIS BY 
CHOLINESTERASES: IMPLICATIONS FOR RADIOTRACER 
DESIGN 
Scott E. Snyder, Xia Shao, Jacinda M. L i d ,  Elizabeth R. Butcht, Marc B. 
Skaddan and Michael R. Kilboum 
Division of Nuclear Medicine, Department of Radiology, University of 
Michigan Medical Center, Ann Arbor, MI 48109 and Department of 
Chemistry, Eastern Michigan University, Ypsilanti, MI 48197. 
t 
Keywords: acetylcholinesterase, butyrylcholinesterase, carbon-I 1 
There is currently great interest in developing radiotracers to estimate 
cortical acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) 
enzymatic activity in Alzheimer’s disease patients using in vivo imaging. 
As part of an ongoing effort to define structure-activity relationships 
(SAR) for cholinesterase substrates, we have recently published in vitro 
and in vivo kinetic results for a series of I-[”C]methyl-4-piperidinyl 
esters (1). These data exhibited the expected preference of AChE for 
short-chain esters (acetate and propionate) and the specificity of longer- 
chain esters (butyrate and pentanoate) for BuChE. We have also shown 
that this general pattern of selectivity extends to the l-methylr3- 
pyrrolidinyl esters, la,b (2). As these latter compounds are chiral, it was 
of interest to extend the SAR to include the effects of stereochemistry on 
enzyme selectivity and cleavage rates. 
Irie. et al. previously reported that the AChE-mediated cleavage rates of 
both the acetate and propionate esters of (R)-l-methyl-3-piperidinol were 
much more rapid than those of the corresponding (S)-enantiomers (3). 
Beckett et al. have reported a similar relationship for the stereoisomers of 
a- and P-methylcholine esters (4,5). In our initial study, racemic 
mixtures of l a  and l b  exhibited iiz vitro AChE-mediated cleavage rates 
similar to the corresponding 4-piperidinyl esters, but the individual 
enantiomers were not tested (2). 
To more clearly define the structure-activity relationships for AChE and 
BuChE with respect to stereochemistry a to the ester functionality, we 
have prepared enantiomerically pure (R)-l-methyl-3-pyrrolidinyl 
propionate, l a  and butyrate, lb,  using the methods previously described 
for 1-methyl-4-piperidinyl propionate, PMP (6). Relative rates of 
substrate cleavage by purified enzymes (AChE or BuChE) were 
determined using a simple in vitro spectrophotometric assay (1). Esters 
l a  and l b  were also labeled with carbon-11, using methods similar to 
those reported for [“CIPMP (6),  and the in vivo biodistribution for each 
in CDll mice was determined. 
Based on the work of Beckett et al. ( 4 3 ,  it would be expected that a 
chiral center p to the ester functionality would also influence enzyme- 
mediated cleavage rates. To address this question we have also prepared 
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chiral esters of (S)-l-methyl-2-pyrrolidinemethanol, 2a-c, and (k)-l- 
methyl-2-piperidinemethano1, 334. In vitro and itz vivo investigations 
similar to those described above are currently underway. 
AhIP, hlP4A R =CH3 
PAIP R = CH2CH3 
l a  R = CH2CH3 
l b  R = CH2CHzCH3 
nBhIP R = CH2CH2CH3 
2a R = CH3 
2b R = CH2CH3 
2~ R = CH2CH2CH3 
3a R = CH3 
3b R =CH2CH3 
3~ R = CH2CH2CH3 
The preliminary in vitro spectrophotometric data for these investigations 
is given in Table 1. (R)-l-methyl-3-pyrrolidinyl propionate, @)la, is 
cleaved by AChE nearly three times faster than both racemic (+.)la and 
PMP (Table l), implying that the (S)-enantiomer of l a  may act as a weak 
AChE inhibitor. A much less dramatic stereochemical preference was 
observed for the BuChE-mediated cleavage of la .  This is also consistent 
with the in vivo distribution in mouse brain shown in Table 2. The 
retention fraction for (R)la was higher than that for both PMP and (*)la 
in all brain areas except striatum. Similarly, the retention fractions for 
(R)lb were higher than those of nBMP in all brain areas. 
The racemic primary ester 3b is also cleaved by AChE more rapidly than 
is PMP. This preference for the primary ester likely arises from the 
shorter amine-to-carbonyl distance in 3b, which better approximates that 
of acetylcholine. In contrast, (S)-l-methyl-2-pyrrolidinemethyl acetate, 
23, is cleaved by AChE at a rate only 1.5 times faster than PMP and 
about one-third the rate of 1-methyl-4-piperidinyl acetate (AMP, MP4A). 
These results indicate that AChE has a preference for the (R)- 
configuration at both the a- and P-positions whereas BuChE has little or 
no stereochemical preference. 
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PMP 
(&)la 
(R)la 
(SPa 
(&)3b 
nBMP 
(&)lb 
Table 1. Relative in vitro ChE-mediated cleavage rates. Rates are determined as a 
change in absorbance (420 nm) of m-nitrophenol per minute per unit of enzyme using 
the indicated substrates and purified AChE or BuChE. Data are expressed relative to 
PMP=100 for AChE and nBMP=100 for BuChE. 
2 M . 3  1 15k2 
17.2M.3 76213 
52+1 1 15&8 
32k1.5 n.d. 
81k1.5 n.d. 
0.00 look3 
0.00 144222 
Substrate AChE BuChE 
PIMP I 0.71M.05 I 0.41M.03 
(rate relative to PMP) (rate relative to nBMP) 
I 33&1 AMP,MP4A 1 1 OW.5 
0.26M.01 I 0.41a.03 0.36a.10 
(R)la 
nBMP 
(R)lb 
Table 2. Retention fractions calculated from in vivo regional distribution in mouse 
brain at 30 min. post-injection relative to initial uptake at 1 min. post-injection. 
Values for PMP and(R)la are an average of 3 experiments (n = 12 total animals per 
time point), nBMP and l b  are an average of 2 experiments (n = 8) and (&)la values 
are from a single study (n = 4). 
0.55M.10 0.51M.09 0.38+0.08 0.53a.08 0.44a.09 
0.11M.03 0.08&02 0.1M.02 0.10M.02 0.12&.W 
0.2M.03 0.15M.02 0.18M.03 0.18a.03 0.23M.03 
(&)la I 0.54M.07 I 0.4M.05 I 0.31M.05 I 0.41M.05 I 0.39M.03 I 
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